Gliptus 50 mg 30 tablets

Trade name:

Glyptus

Gliptus

Composition

Each tablet contains:

Vildagliptin 50 mg

Auxiliary components:

Microcrystalline cellulose, anhydrous lactose, magnesium stearate.

Properties

Hypoglycemic agent. Vildagliptin is a representative of the class of stimulants of the islet apparatus of the pancreas; it selectively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). Rapid and complete inhibition of DPP-4 activity (> 90%) causes an increase in both basal and food-stimulated secretion of glucagon-like peptide type 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) from the intestine into the systemic circulation throughout the day.

Indications

Type 2 diabetes mellitus: as monotherapy in combination with diet therapy and exercise; as part of a two-component combination therapy with metformin, sulfonylurea derivatives, thiazolidinedione or insulin in case of ineffectiveness of diet therapy, exercise and monotherapy with these drugs.

Method of administration and dosage:

The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

Contraindications

Hypersensitivity to vildagliptin.

Precautionary measures:

It is not recommended for use in patients with severely impaired liver function, incl. with an increase in ALT or AST activity> 2.5 times higher than ULN.

Side effects

From the digestive system: sometimes — constipation; rarely — dysfunction of the liver (including hepatitis) asymptomatic; when combined with insulin, often — nausea, flatulence, GERD.

From the side of the central nervous system: often — tremor, dizziness, headache.

From the side of metabolism: often — hypoglycemia, weight gain.